We are live on ! Find out more
HTGM

HTG Molecular Diagnostics, Inc. Common Stock

Delisted

HTGM was delisted on the 14th of June, 2023.

41 hedge funds and large institutions have $40.5M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 9 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,400% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 1

869% more capital invested

Capital invested by funds: $4.18M → $40.5M (+$36.3M)

800% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 1

141% more funds holding

Funds holding: 1741 (+24)

Holders
41
Holders Change
+24
Holders Change %
+141.18%
% of All Funds
0.94%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
25
Increased
9
Reduced
1
Closed
1
Calls
Puts
Net Calls
Net Calls Change

HTGM Hedge Fund Activity: Q1 2018 in Review

41 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q1 2018, worth a combined $40.5M — up 869% from $4.18M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new HTGM positions and 1 closed out — a net gain of 24 holders — while 9 added to existing stakes and 1 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $11.6M. The largest seller was Oxford Asset Management, exiting entirely with an estimated $81K sold.

  • 41 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q1 2018, up from 17 in Q4 2017.
  • Funds reported $40.5M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q1 2018, up 869% quarter-over-quarter.
  • 25 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q1 2018 and 1 closed out, a net change of +24 holders.
  • The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q1 2018 was Fidelity Investments, an estimated $11.6M added.
  • The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q1 2018 was Oxford Asset Management, an estimated $81K sold.

Based on aggregated 13F filings for Q1 2018.